For EGPA, FASENRA is 1 injection administered every 4 weeks. Fewer injections than other EGPA treatment options†
Find out more about the signs and symptoms of EGPA
Discover the ways
you can save on FASENRA
Ask your doctor if FASENRA is right for you.
†Dosing comparisons do not imply improved efficacy or safety.
frequently asked questions
FASENRA is a prescription medicine approved to help treat people 18 years and older with EGPA. It's a biologic treatment given by injection once every 4 weeks.
The mechanism of action of FASENRA in EGPA is not fully understood.
Achieving remission may be possible – Learn about the impact FASENRA had on steroid use in patients with EGPA.
59% of patients in a clinical trial were in remission at both 36 and 48 weeks. This means no active EGPA disease activity* and daily oral steroid use of 4 mg or less.
Versus 57% of patients in the control group.
With FASENRA, 41% of people in a clinical study no longer required oral steroids.†‡
Versus 26% of patients in the control group.†‡
86% of patients with EGPA taking FASENRA reduced their dose of oral steroids by 50% or more.†‡
Versus 74% of patients in the control group.†‡
Do not stop or change your corticosteroid medicines unless instructed by your healthcare provider.
Results May Vary
70% of patients in each group remained relapse-free during the study. Relapse is defined as the return of disease symptoms after a period of improvement or remission.
In the 52-week study, FASENRA was studied against mepolizumab (control group, which is an active comparator) in a total of 140 patients (70 for each product). FASENRA was administered 1 injection every 4 weeks, compared with mepolizumab administered 3 injections every 4 weeks. The results across the study were comparable.
*Remission is defined as no active vasculitis and daily oral steroid use of 4 mg or less.
†Oral steroid dose compared to baseline in the last 4 weeks of treatment (weeks 48-52).
‡Based on the design of the study, results are descriptive.
IMPORTANT SAFETY INFORMATION
Do not use FASENRA if you are allergic to benralizumab or any of the ingredients in FASENRA. Do not use to treat sudden breathing problems.
FASENRA may cause serious side effects, including:
- allergic (hypersensitivity) reactions, including anaphylaxis. Serious allergic reactions can happen after you get your FASENRA injection. Allergic reactions can sometimes happen hours or days after you get your injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:
- swelling of your face, mouth and tongue
- breathing problems
- fainting, dizziness, feeling lightheaded (low blood pressure)
- rash
- hives
Before using FASENRA, tell your healthcare provider about all of your medical conditions, including if you:
- are taking oral or inhaled corticosteroid medicines. Do not stop taking your corticosteroid medicines unless instructed by your healthcare provider. This may cause other symptoms that were controlled by the corticosteroid medicine to come back
- have a parasitic (helminth) infection
- are pregnant or plan to become pregnant. It is not known if FASENRA will harm your unborn baby. Tell your healthcare provider if you become pregnant during your treatment with FASENRA
- are breastfeeding or plan to breastfeed. It is not known if FASENRA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you use FASENRA
- are taking prescription and over-the-counter medicines, vitamins, or herbal supplements.
Do not stop taking your other medicines unless instructed to do so by your healthcare provider. Tell your healthcare provider if your condition does not get better or if it gets worse after you start treatment with FASENRA.
The most common side effects of FASENRA:
- adults and children 6 years and older with asthma include headache and sore throat
- adults with EGPA include headache
- adults and children 12 years and older with HES include headache, allergic reactions, and flu-like symptoms
These are not all the possible side effects of FASENRA.
APPROVED USE
FASENRA is a prescription medicine used:
- with other asthma medicines for the maintenance treatment of asthma in adults and children 6 years and older whose asthma is not controlled with their current asthma medicines. FASENRA is not used to treat sudden breathing problems.
- to treat adults with eosinophilic granulomatosis with polyangiitis (EGPA).
- to treat adults and children 12 years and older with hypereosinophilic syndrome (HES).
Please see full Prescribing Information, including Patient Information and Instructions for Use.
You may report side effects related to AstraZeneca products.
